title: [New perspectives in prostate cancer management].
abstract: The treatment of prostate cancer is experiencing important innovations. Hormone therapy includes a new class of drugs: LHRH antagonists, which induce a rapid, fast and sustained reduction of testosterone levels. Active surveillance enables to avoid an aggressive treatment without decreasing survival, provided that strict eligibility and follow-up criteria are applied. New imaging techniques and laboratory assays lead to early diagnosis of small size tumors. Lastly, focal therapy has the potential to target localized cancers without deterioration of surrounding structures. These concomitant improvements offer the clinician and the patient attractive options for prostate cancer management. However, they are not devoid of limitations and constraints. Thus, it is crucial to define the most appropriate patient's profile for each therapeutic option, taking into account the objective characteristics of the tumor and the psychological features of the patient.
authors.affiliation: Clinique urologie, hôpital Bichat-Claude-Bernard, université Paris VII Denis-Diderot, 46, rue Henri-Huchard, 75877 Paris cedex 18, France.
authors.forename: L
authors.initials: L
authors.lastname: Boccon-Gibod
authors.forename: J-L
authors.initials: JL
authors.lastname: Davin
authors.forename: C
authors.initials: C
authors.lastname: Coulange
authors.forename: S
authors.initials: S
authors.lastname: Culine
authors.forename: P
authors.initials: P
authors.lastname: Coloby
authors.forename: M
authors.initials: M
authors.lastname: Soulié
authors.forename: M
authors.initials: M
authors.lastname: Zerbib
authors.forename: P
authors.initials: P
authors.lastname: Richaud
mesh_terms: D005544:Forecasting; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000628:therapy*